BGI Genomics Co., Ltd. (hereinafter referred to as "the Company" or "BGI Genomics") notes that the Bureau of Industry and Security, U.S. Department of Commerce, updated an Entity List on March 2, 2023, to include BGI Tech Solutions (Hongkong) Co., Ltd. (hereinafter referred to as "BGI Tech"), a subsidiary of BGI Genomics.

Focusing on life science and gene technology, BGI Genomics is committed to enhancing health outcomes worldwide. The Company advances public health in various countries and regions in compliance with local and international laws and regulations. BGI Genomics' services and products are not used for military purposes and intended for civilian or commercial use only.

The Company is seeking additional details from the Bureau of Industry and Security about the specific reasons for BGI Tech's inclusion in the Entity List. BGI Tech's operating revenue in financial year 2022 is a relatively small percentage of BGI Genomics revenue. The inclusion of BGI Tech in the Entity List will not have a material impact on the Company's operations. At present, the Company's production and financial situation are not impacted as regular operations continue. BGI Genomics will continue to respond to developments as appropriate, and proactively maintain communication with relevant departments and stakeholders.